BIOTRON LIMITED - Announcements

0.00%

0.2¢

Market Cap $2.654M

Healthcare Biotechnology

Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the... Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The Company also has a portfolio of preclinical antiviral programs.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

BIT	Change of Director's Interest Notice		29/11/22	250.15KB	Share
BIT	Notification of cessation of securities - BIT		28/11/22	21.5KB	Share
BIT	Cleansing Notice		25/11/22	97.91KB	Share
BIT	Listed Options Information		25/11/22	98.9KB	Share
BIT	Application for quotation of securities		25/11/22	358.97KB	Share
BIT	Application for quotation of securities - BIT		25/11/22	29.22KB	Share
BIT	Proposed issue of securities - BIT		24/11/22	27.45KB	Share
BIT	Rights Issue Closed	PRICE SENSITIVE	24/11/22	174.24KB	Share
BIT	Supplementary Prospectus	PRICE SENSITIVE	24/11/22	139.65KB	Share
BIT	Cancel - Proposed issue of securities - BIT		22/11/22	38.86KB	Share
BIT	Appendix 3B		21/11/22	753.77KB	Share
BIT	$1.43M R&D rebate received	PRICE SENSITIVE	18/11/22	148.2KB	Share
BIT	Results of Annual General Meeting		16/11/22	173.02KB	Share
BIT	Chairman's Address and Presentation to AGM		16/11/22	370.97KB	Share
BIT	Presentation to Investors		11/11/22	408.74KB	Share
BIT	Clarification of Fractional Entitlements		07/11/22	112.37KB	Share
BIT	Commencement of Rights Trading - BITRC	PRICE SENSITIVE	31/10/22	128.29KB	Share
BIT	Letter to Shareholders		31/10/22	370.18KB	Share
BIT	Prospectus	PRICE SENSITIVE	27/10/22	683.43KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	27/10/22	190.28KB	Share
BIT	Proposed issue of securities - BIT		27/10/22	39.21KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/10/22	422.98KB	Share
BIT	Annual Report and Notice of Annual General Meeting		14/10/22	2.98MB	Share
BIT	Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	04/10/22	181.16KB	Share
BIT	Bit225 Covid-19 Human Study Commenced	PRICE SENSITIVE	14/09/22	175.41KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	23/08/22	154.11KB	Share
BIT	Appendix 4G and Corporate Governance Statement		19/08/22	638.34KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	19/08/22	670.98KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	1.04MB	Share
BIT	POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM	PRICE SENSITIVE	30/05/22	130.47KB	Share
BIT	BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PRICE SENSITIVE	02/05/22	353.01KB	Share
BIT	Quarterly Cash Flow Report Appendix 4C	PRICE SENSITIVE	26/04/22	250.36KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	26/04/22	137.32KB	Share
BIT	$1.56M R&D Rebate Received	PRICE SENSITIVE	05/04/22	147.99KB	Share
BIT	BIT225 Effectiveness Against COVID-19 in Animals	PRICE SENSITIVE	17/03/22	214.51KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/22	630.82KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	135.98KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	248.82KB	Share
BIT	Update on Biotron HIV-1 And COVID-19 Programs		16/12/21	406.87KB	Share
BIT	Notification of cessation of securities - BIT		06/12/21	21.5KB	Share
BIT	BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PRICE SENSITIVE	25/11/21	594.07KB	Share
BIT	Results of Meeting		23/11/21	159.5KB	Share
BIT	Chairman's Address and Presentation to AGM		23/11/21	482.81KB	Share
BIT	COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS	PRICE SENSITIVE	01/11/21	157.65KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/10/21	140.11KB	Share
BIT	Quarterly Cash Flow Report	PRICE SENSITIVE	28/10/21	155.44KB	Share
BIT	Annual Report and Notice of Annual General Meeting		20/10/21	2.79MB	Share
BIT	Full Year Statutory Accounts and Preliminary Final Report	PRICE SENSITIVE	27/08/21	951.58KB	Share
BIT	Appendix 4G and Corporate Governance Statement		27/08/21	677.29KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	30/07/21	141.42KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/21	155.38KB	Share
BIT	Letter to Shareholders		08/07/21	244.22KB	Share
BIT	Notification of cessation of securities - BIT		01/07/21	21.59KB	Share
BIT	$1.4M R&D Tax Rebate	PRICE SENSITIVE	29/04/21	117.13KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/04/21	140.53KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/21	155.05KB	Share
BIT	Lead Series for SARS-COV-2 Program		11/03/21	107.54KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/21	447.04KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/01/21	141.92KB	Share
BIT	Quarterly Cashflow Report	PRICE SENSITIVE	29/01/21	155.26KB	Share
BIT	Results of Meeting		19/11/20	157.7KB	Share
BIT	Presentation to Annual General Meeting		19/11/20	373.06KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/10/20	143.32KB	Share
BIT	Quarterly Cashflow Report	PRICE SENSITIVE	29/10/20	155.86KB	Share
BIT	BIT225 HIV-1 Immunomodulatory Paper Published		15/10/20	119.59KB	Share
BIT	Presentation to Investors		14/10/20	518.47KB	Share
BIT	Annual Report and Notice of Annual General Meeting		09/10/20	8.31MB	Share
BIT	Biotron Compounds Show Activity Against SARS-CoV-2 Virus	PRICE SENSITIVE	07/09/20	141.9KB	Share
BIT	Trading Halt	PRICE SENSITIVE	03/09/20	114.48KB	Share
BIT	Pause in Trading	PRICE SENSITIVE	03/09/20	115.52KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	27/08/20	677.29KB	Share
BIT	Appendix 4G and Corporate Governance Statement		27/08/20	392.94KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/07/20	141.46KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/20	155.99KB	Share
BIT	Letter to Shareholders		22/07/20	282.84KB	Share
BIT	Appointment of Chief Medical Officer		17/07/20	83.83KB	Share
BIT	BIT225 Reverses HIV-Induced Immune Evasion	PRICE SENSITIVE	06/07/20	669.54KB	Share
BIT	Latest BIT225data presented at International Aids Conference		22/06/20	100.6KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	23/04/20	144.47KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	23/04/20	164.52KB	Share
BIT	R&D Tax Refund Received	PRICE SENSITIVE	19/03/20	111.09KB	Share
BIT	BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS	PRICE SENSITIVE	12/03/20	747.75KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	1.73MB	Share
BIT	Letter to Shareholders		25/02/20	250.08KB	Share
BIT	Biotron to Test its Compounds Against Coronavirus	PRICE SENSITIVE	06/02/20	226.09KB	Share
BIT	Appendix 3B		31/01/20	654.69KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/20	702.24KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	23/01/20	620.57KB	Share
BIT	Change of Director's Interest Notice		22/01/20	552.35KB	Share
BIT	Change of Director's Interest Notice		13/01/20	551.79KB	Share
BIT	Appendix 3B and Appendix 3Y		23/12/19	213.19KB	Share
BIT	Appendix 2A		23/12/19	169.96KB	Share
BIT	Appendix 2A		17/12/19	423.45KB	Share
BIT	Appendix 2A		11/12/19	169.86KB	Share
BIT	Change of Director's Interest Notice		10/12/19	173.54KB	Share
BIT	Change of Director's Interest Notice		05/12/19	641.06KB	Share
BIT	Appendix 2A		05/12/19	490.67KB	Share
BIT	Presentation of HIV Data to CROI and New Patents		03/12/19	100.78KB	Share
BIT	Appendix 3B		28/11/19	983.36KB	Share
BIT	Results of Meeting		26/11/19	332.31KB	Share

BIT Change of Director's Interest Notice
29/11/22		250.15KB	Share
BIT Notification of cessation of securities - BIT
28/11/22		21.5KB	Share
BIT Cleansing Notice
25/11/22		97.91KB	Share
BIT Listed Options Information
25/11/22		98.9KB	Share
BIT Application for quotation of securities
25/11/22		358.97KB	Share
BIT Application for quotation of securities - BIT
25/11/22		29.22KB	Share
BIT Proposed issue of securities - BIT
24/11/22		27.45KB	Share
BIT Rights Issue Closed
24/11/22	PRICE SENSITIVE	174.24KB	Share
BIT Supplementary Prospectus
24/11/22	PRICE SENSITIVE	139.65KB	Share
BIT Cancel - Proposed issue of securities - BIT
22/11/22		38.86KB	Share
BIT Appendix 3B
21/11/22		753.77KB	Share
BIT $1.43M R&D rebate received
18/11/22	PRICE SENSITIVE	148.2KB	Share
BIT Results of Annual General Meeting
16/11/22		173.02KB	Share
BIT Chairman's Address and Presentation to AGM
16/11/22		370.97KB	Share
BIT Presentation to Investors
11/11/22		408.74KB	Share
BIT Clarification of Fractional Entitlements
07/11/22		112.37KB	Share
BIT Commencement of Rights Trading - BITRC
31/10/22	PRICE SENSITIVE	128.29KB	Share
BIT Letter to Shareholders
31/10/22		370.18KB	Share
BIT Prospectus
27/10/22	PRICE SENSITIVE	683.43KB	Share
BIT Renounceable Issue
27/10/22	PRICE SENSITIVE	190.28KB	Share
BIT Proposed issue of securities - BIT
27/10/22		39.21KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/10/22	PRICE SENSITIVE	422.98KB	Share
BIT Annual Report and Notice of Annual General Meeting
14/10/22		2.98MB	Share
BIT Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
04/10/22	PRICE SENSITIVE	181.16KB	Share
BIT Bit225 Covid-19 Human Study Commenced
14/09/22	PRICE SENSITIVE	175.41KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
23/08/22	PRICE SENSITIVE	154.11KB	Share
BIT Appendix 4G and Corporate Governance Statement
19/08/22		638.34KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
19/08/22	PRICE SENSITIVE	670.98KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	1.04MB	Share
BIT POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
30/05/22	PRICE SENSITIVE	130.47KB	Share
BIT BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
02/05/22	PRICE SENSITIVE	353.01KB	Share
BIT Quarterly Cash Flow Report Appendix 4C
26/04/22	PRICE SENSITIVE	250.36KB	Share
BIT Quarterly Activities Report
26/04/22	PRICE SENSITIVE	137.32KB	Share
BIT $1.56M R&D Rebate Received
05/04/22	PRICE SENSITIVE	147.99KB	Share
BIT BIT225 Effectiveness Against COVID-19 in Animals
17/03/22	PRICE SENSITIVE	214.51KB	Share
BIT Half Yearly Report and Accounts
23/02/22	PRICE SENSITIVE	630.82KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	135.98KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	248.82KB	Share
BIT Update on Biotron HIV-1 And COVID-19 Programs
16/12/21		406.87KB	Share
BIT Notification of cessation of securities - BIT
06/12/21		21.5KB	Share
BIT BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS
25/11/21	PRICE SENSITIVE	594.07KB	Share
BIT Results of Meeting
23/11/21		159.5KB	Share
BIT Chairman's Address and Presentation to AGM
23/11/21		482.81KB	Share
BIT COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
01/11/21	PRICE SENSITIVE	157.65KB	Share
BIT Quarterly Activities Report
28/10/21	PRICE SENSITIVE	140.11KB	Share
BIT Quarterly Cash Flow Report
28/10/21	PRICE SENSITIVE	155.44KB	Share
BIT Annual Report and Notice of Annual General Meeting
20/10/21		2.79MB	Share
BIT Full Year Statutory Accounts and Preliminary Final Report
27/08/21	PRICE SENSITIVE	951.58KB	Share
BIT Appendix 4G and Corporate Governance Statement
27/08/21		677.29KB	Share
BIT Quarterly Activities Report
30/07/21	PRICE SENSITIVE	141.42KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
30/07/21	PRICE SENSITIVE	155.38KB	Share
BIT Letter to Shareholders
08/07/21		244.22KB	Share
BIT Notification of cessation of securities - BIT
01/07/21		21.59KB	Share
BIT $1.4M R&D Tax Rebate
29/04/21	PRICE SENSITIVE	117.13KB	Share
BIT Quarterly Activities Report
28/04/21	PRICE SENSITIVE	140.53KB	Share
BIT Appendix 4C - quarterly
28/04/21	PRICE SENSITIVE	155.05KB	Share
BIT Lead Series for SARS-COV-2 Program
11/03/21		107.54KB	Share
BIT Half Yearly Report and Accounts
23/02/21	PRICE SENSITIVE	447.04KB	Share
BIT Quarterly Activities Report
29/01/21	PRICE SENSITIVE	141.92KB	Share
BIT Quarterly Cashflow Report
29/01/21	PRICE SENSITIVE	155.26KB	Share
BIT Results of Meeting
19/11/20		157.7KB	Share
BIT Presentation to Annual General Meeting
19/11/20		373.06KB	Share
BIT Quarterly Activities Report
29/10/20	PRICE SENSITIVE	143.32KB	Share
BIT Quarterly Cashflow Report
29/10/20	PRICE SENSITIVE	155.86KB	Share
BIT BIT225 HIV-1 Immunomodulatory Paper Published
15/10/20		119.59KB	Share
BIT Presentation to Investors
14/10/20		518.47KB	Share
BIT Annual Report and Notice of Annual General Meeting
09/10/20		8.31MB	Share
BIT Biotron Compounds Show Activity Against SARS-CoV-2 Virus
07/09/20	PRICE SENSITIVE	141.9KB	Share
BIT Trading Halt
03/09/20	PRICE SENSITIVE	114.48KB	Share
BIT Pause in Trading
03/09/20	PRICE SENSITIVE	115.52KB	Share
BIT Full Year Statutory Accounts
27/08/20	PRICE SENSITIVE	677.29KB	Share
BIT Appendix 4G and Corporate Governance Statement
27/08/20		392.94KB	Share
BIT Quarterly Activities Report
29/07/20	PRICE SENSITIVE	141.46KB	Share
BIT Appendix 4C - quarterly
29/07/20	PRICE SENSITIVE	155.99KB	Share
BIT Letter to Shareholders
22/07/20		282.84KB	Share
BIT Appointment of Chief Medical Officer
17/07/20		83.83KB	Share
BIT BIT225 Reverses HIV-Induced Immune Evasion
06/07/20	PRICE SENSITIVE	669.54KB	Share
BIT Latest BIT225data presented at International Aids Conference
22/06/20		100.6KB	Share
BIT Quarterly Activities Report
23/04/20	PRICE SENSITIVE	144.47KB	Share
BIT Appendix 4C - quarterly
23/04/20	PRICE SENSITIVE	164.52KB	Share
BIT R&D Tax Refund Received
19/03/20	PRICE SENSITIVE	111.09KB	Share
BIT BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS
12/03/20	PRICE SENSITIVE	747.75KB	Share
BIT Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	1.73MB	Share
BIT Letter to Shareholders
25/02/20		250.08KB	Share
BIT Biotron to Test its Compounds Against Coronavirus
06/02/20	PRICE SENSITIVE	226.09KB	Share
BIT Appendix 3B
31/01/20		654.69KB	Share
BIT Appendix 4C - quarterly
24/01/20	PRICE SENSITIVE	702.24KB	Share
BIT Response to ASX Price Query
23/01/20	PRICE SENSITIVE	620.57KB	Share
BIT Change of Director's Interest Notice
22/01/20		552.35KB	Share
BIT Change of Director's Interest Notice
13/01/20		551.79KB	Share
BIT Appendix 3B and Appendix 3Y
23/12/19		213.19KB	Share
BIT Appendix 2A
23/12/19		169.96KB	Share
BIT Appendix 2A
17/12/19		423.45KB	Share
BIT Appendix 2A
11/12/19		169.86KB	Share
BIT Change of Director's Interest Notice
10/12/19		173.54KB	Share
BIT Change of Director's Interest Notice
05/12/19		641.06KB	Share
BIT Appendix 2A
05/12/19		490.67KB	Share
BIT Presentation of HIV Data to CROI and New Patents
03/12/19		100.78KB	Share
BIT Appendix 3B
28/11/19		983.36KB	Share
BIT Results of Meeting
26/11/19		332.31KB	Share

REFRESH

First 2 3 4 5

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $2.654M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
46	35768629	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	15608555	20

View Market Depth

No.	Vol.	Price($)
46	35768629	0.002
32	93302000	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	15608555	20
0.004	16987080	16
0.005	6690600	5
0.006	1200000	2
0.007	572733	2

Last trade - 09.59am 31/07/2025 (20 minute delay)

BIT (ASX) Chart

Day chart unavailable

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available